Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Renal Insufficiency, Chronic 1Non-alcoholic Fatty Liver Disease 1Liver Cirrhosis, Alcoholic 1Hypothermia 1Hepatitis C 1Hepatitis B 1Fibrosis 1End Stage Liver Disease 1Carcinoma, Hepatocellular 1Acute Kidney Injury 1

Interventions

Sorafenib 222lenvatinib 147Bevacizumab 131Nivolumab 87atezolizumab 81pembrolizumab 74Radiosurgery 71durvalumab 63sintilimab 61Oxaliplatin 60Fluorouracil 56Doxorubicin 47tislelizumab 46apatinib 45Radiofrequency Ablation 44Hepatectomy 43camrelizumab 41Leucovorin 41Radiotherapy 40tremelimumab 37Magnetic Resonance Spectroscopy 36regorafenib 34Capecitabine 30Immune Checkpoint Inhibitors 29Folfox protocol 29Cisplatin 28cabozantinib 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Hypothermia, Induced × Clear all
NCT03534141 2025-05-16

MHALT

University of California, San Francisco

Phase NA Terminated
175 enrolled 19 charts
GastrointestinalGenitourinary

Fibrosis, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, Hypothermia, Liver Cirrhosis, Alcoholic, Renal Insufficiency, Chronic, Acute Kidney Injury, End Stage Liver Disease, Non-alcoholic Fatty Liver Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡